• Safi Bello

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation In The European Union For The Treatm

Pfizer press release ------- Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). XELJANZ can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. XELJANZ belongs to a new class of therapies called Janus kinase (JAK) inhibitors. To get more in depth information click on the picture below to read the release.

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation In The European Union For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis (RA) - Read More from Pfizer

1 view
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon